Homeopathy is the second most used system of traditional medicine in the world, practiced by millions of people across many countries.

Today, a new allergy treatment is drawing attention because it uses ideas that are familiar to homeopathic medicine.

Pharmaceutical companies Merck and ALK have helped develop a daily pill for people who are allergic to dust mites. This treatment is called sublingual immunotherapy, often shortened to SLIT.

The pill is taken by placing it under the tongue each day.

How Does the Dust Mite Allergy Pill Work?

The pill contains a very small amount of dust mite material. The goal is to help the body slowly become more comfortable with dust mites, so allergy symptoms may lessen over time.

This method focuses on working with the body’s immune system rather than only blocking symptoms.

How Is This Similar to Homeopathy?

Many people notice that sublingual immunotherapy shares important ideas with homeopathy.

• Using the same substance
  In homeopathy, the substance linked to symptoms is also used as part of the treatment. In this case, dust mites are used to help the body respond more calmly to dust mites.

• Taken under the tongue
  Homeopathic remedies are often taken under the tongue. Sublingual immunotherapy uses the same method.

• Supporting balance in the body
  Both approaches focus on helping the body return to a balanced, healthier response.

  Why This Is Interesting

  Homeopathy has been used around the world for over 200 years. Seeing similar ideas appear in modern pharmaceutical treatments shows how different medical traditions can share common goals.

  Many readers find it meaningful that approaches used in traditional medicine are also reflected in newer allergy treatments.

References

• A large Phase III clinical trial showed a sublingual tablet for dust-mite allergy was effective and safe in over 1,600 people, supporting its use for allergic rhinitis. PubMed

• Merck announced results of its dust mite sublingual immunotherapy tablet in clinical trials, highlighting its ongoing development.Merck.com

• Merck and ALK partnered to seek FDA review of a house dust mite sublingual immunotherapy tablet, showing industry support and regulatory engagement. Merck.com

• A randomized clinical trial published in JAMA evaluated dust mite sublingual immunotherapy tablets in adults and adolescents and found measurable improvement in allergy symptoms.JAMA Network

• The FDA has approved ALK’s ODACTRA® sublingual tablet for treating house dust mite–induced allergic rhinitis in adolescents and adults. PR Newswire